Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/182346
IPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Myocardial infarction is the main driver of heart failure due to ischemia and subsequent cell death, and cell-based strategies have emerged as promising therapeutic methods to replace dead tissue in cardiovascular diseases. Research in this field has been dramatically advanced by the development of laboratory-induced pluripotent stem cells (iPSCs) that harbor the capability to become any cell type. Like other experimental strategies, stem cell therapy must meet multiple requirements before reaching the clinical trial phase, and in vivo models are indispensable for ensuring the safety of such novel therapies. Specifically, translational studies in large animal models are necessary to fully evaluate the therapeutic potential of this approach; to empirically determine the optimal combination of cell types, supplementary factors, and delivery methods to maximize efficacy; and to stringently assess safety. In the present review, we summarize the main strategies employed to generate iPSCs and differentiate them into cardiomyocytes in large animal species; the most critical differences between using small versus large animal models for cardiovascular studies; and the strategies that have been pursued regarding implanted cells' stage of differentiation, origin, and technical application.
Subject (English)
Citation
Citation
MARTÍNEZ FALGUERA, Daina, IBORRA EGEA, Oriol and GÁLVEZ MONTÓN, Carolina. IPSC Therapy for Myocardial Infarction in Large Animal Models: Land of Hope and Dreams. Biomedicines. 2021. Vol. 9, num. 12, pags. 1836. [consulted: 14 of June of 2026]. Available at: https://hdl.handle.net/2445/182346